Christophe Soulier
Finanzdirektor/CFO bei Janssen Pharmaceuticals, Inc.
Profil
Christophe Soulier is currently the Director-Global Finance, Research & Development at Janssen Pharmaceuticals, Inc. since 2011.
He is also currently the Director at Johnson & Johnson Innovation Ltd.
starting in 2023.
Previously, he worked as the Finance Director at Johnson & Johnson from 2005 to 2007.
Mr. Soulier holds an MBA from the University of Michigan, which he obtained in 2002.
He also completed his undergraduate studies at Collège Stanislas de Paris in 1989.
Aktive Positionen von Christophe Soulier
| Unternehmen | Position | Beginn |
|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Finanzdirektor/CFO | 01.11.2007 |
Johnson & Johnson Innovation Ltd.
 Johnson & Johnson Innovation Ltd. Investment ManagersFinance Johnson & Johnson Innovation Ltd is a private equity subsidiary of Johnson & Johnson Innovation - JJDC, Inc. founded in 2000. The firm is headquartered in Buckinghamshire, United Kingdom. | Private Equity Investor | 08.02.2023 |
Ehemalige bekannte Positionen von Christophe Soulier
| Unternehmen | Position | Ende |
|---|---|---|
| JOHNSON & JOHNSON | Finanzdirektor/CFO | 01.10.2007 |
Ausbildung von Christophe Soulier
| University of Michigan | Masters Business Admin |
| Collège Stanislas de Paris | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Johnson & Johnson Innovation Ltd.
Johnson & Johnson Innovation Ltd. Investment ManagersFinance Johnson & Johnson Innovation Ltd is a private equity subsidiary of Johnson & Johnson Innovation - JJDC, Inc. founded in 2000. The firm is headquartered in Buckinghamshire, United Kingdom. | Finance |
